{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:36:37Z","timestamp":1788870997085,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Science and Technology, India","award":["DST\/INSPIRE Fellowship\/239B"],"award-info":[{"award-number":["DST\/INSPIRE Fellowship\/239B"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.parint.2014.10.003","type":"journal-article","created":{"date-parts":[[2014,10,12]],"date-time":"2014-10-12T10:21:02Z","timestamp":1413109262000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis"],"prefix":"10.1016","volume":"64","author":[{"given":"Ankita","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parint.2014.10.003_bb0005","series-title":"Leishmaniasis","author":"World Health Organization","year":"2014"},{"issue":"6","key":"10.1016\/j.parint.2014.10.003_bb0010","doi-asserted-by":"crossref","first-page":"e2278","DOI":"10.1371\/journal.pntd.0002278","article-title":"A review of preventative methods against human leishmaniasis infection","volume":"7","author":"Stockdale","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.parint.2014.10.003_bb0015","first-page":"9","article-title":"Current treatment of leishmaniasis: a review","volume":"1","author":"Monzote","year":"2009","journal-title":"Open Antimicrob Agents J"},{"key":"10.1016\/j.parint.2014.10.003_bb0020","unstructured":"Rattue G. Visceral Leishmaniasis Vaccine Trial Commences. Medical News Today 2012. Available at: http:\/\/www.medicalnewstoday.com\/articles\/242247.php. (Accessed 23 September 2013)."},{"key":"10.1016\/j.parint.2014.10.003_bb0025","doi-asserted-by":"crossref","first-page":"697-09","DOI":"10.2174\/1566524043360212","article-title":"Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis","volume":"4","author":"Ravindran","year":"2004","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.parint.2014.10.003_bb0030","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0035","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0040","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20020147","article-title":"Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection","volume":"195","author":"Rhee","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.parint.2014.10.003_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S0031182003003457","article-title":"Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis","volume":"127","author":"Srivastava","year":"2003","journal-title":"Parasitology"},{"key":"10.1016\/j.parint.2014.10.003_bb0050","first-page":"159","article-title":"The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis","volume":"36","author":"Michel","year":"2006","journal-title":"J Egypt Soc Parasitol"},{"key":"10.1016\/j.parint.2014.10.003_bb0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.parint.2009.07.008","article-title":"Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis","volume":"58","author":"Nagill","year":"2009","journal-title":"Parasitol"},{"key":"10.1016\/j.parint.2014.10.003_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum precipitated autoclaved L. major plus BCG, a candidate vaccine for visceral leishmaniasis: safety, skin delayed hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.parint.2014.10.003_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major+BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.parint.2014.10.003_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"Ghalib","year":"2007","journal-title":"Kinetoplastid Biol Dis"},{"key":"10.1016\/j.parint.2014.10.003_bb0075","doi-asserted-by":"crossref","first-page":"58-3","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"Musa","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.parint.2014.10.003_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00436-008-0921-8","article-title":"Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis","volume":"103","author":"Keshavarz Valian","year":"2008","journal-title":"Parasitol Res"},{"key":"10.1016\/j.parint.2014.10.003_bb0085","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.parint.2014.10.003_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00144","article-title":"Adjuvants for Leishmania vaccines: from models to clinical application","author":"Raman","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0095","doi-asserted-by":"crossref","first-page":"996-02","DOI":"10.1038\/nm.2403","article-title":"DNA released from dying host cells mediates aluminum adjuvant activity","volume":"17","author":"Marichal","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.parint.2014.10.003_bb0365","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.163.8.4481","article-title":"Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis","volume":"163","author":"Kenney","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-3024.2011.01318.x","article-title":"Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB\/c mice","volume":"33","author":"Soudi","year":"2011","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(98)00013-1","article-title":"ISCOMs and other saponin based adjuvants","volume":"32","author":"Barr","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.parint.2014.10.003_bb0110","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0115","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00ae vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0923-2494(92)80058-S","article-title":"Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity","volume":"143","author":"Gustafson","year":"1992","journal-title":"Res Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0125","first-page":"495-24","article-title":"Monophosphoryl lipid A as an adjuvant: past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.parint.2014.10.003_bb0130","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.vaccine.2005.03.019","article-title":"Phase I safety and immunogenicity of RTS, S\/AS02A candidate malaria vaccine in Gambian children","volume":"23","author":"Bojang","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0135","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.micinf.2005.03.011","article-title":"Tuberculosis vaccine development; from mouse to man","volume":"7","author":"Reed","year":"2005","journal-title":"Microbes Infect"},{"key":"10.1016\/j.parint.2014.10.003_bb0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.parint.2014.10.003_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4419-1603-7_10","article-title":"Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results","volume":"667","author":"Cluff","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.parint.2014.10.003_bb0150","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.vaccine.2012.01.070","article-title":"Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens","volume":"30","author":"Watson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0155","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.vaccine.2010.01.015","article-title":"Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis","volume":"28","author":"Nagill","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2180-10-181","article-title":"Comparison of BCG MPL and cationic liposome adjuvant systems in leishmanial antigen formulations against murine visceral leishmaniasis","volume":"10","author":"Ravindran","year":"2010","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.parint.2014.10.003_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00436-011-2806-5","article-title":"Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis","volume":"111","author":"Shargh","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.parint.2014.10.003_bb0170","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/IAI.65.6.2371-2377.1997","article-title":"Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes","volume":"65","author":"Afrin","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.parint.2014.10.003_bb0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.parint.2014.10.003_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parint.2013.09.016","article-title":"Asparagus racemosus ameliorates cisplatin induced toxicities and augments its antileishmanial activity by immunomodulation in vivo","volume":"63","author":"Sachdeva","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.parint.2014.10.003_bb0185","first-page":"119","article-title":"Regulation of Leishmania population within the host. I. the variable course of Leishmania donovani infections in mice","volume":"30","author":"Bradley","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0190","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00436-008-1150-x","article-title":"Effect of dose and route of inoculation on the generation of CD4+ Th1\/Th2 type of immune response in murine visceral leishmaniasis","volume":"103","author":"Kaur","year":"2008","journal-title":"Parasitol Res"},{"key":"10.1016\/j.parint.2014.10.003_bb0195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/IAI.72.2.863-870.2004","article-title":"Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy","volume":"72","author":"Ravindran","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.parint.2014.10.003_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2012.00099","article-title":"Vaccine development against Leishmania donovani","volume":"3","author":"Das","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0205","doi-asserted-by":"crossref","first-page":"13951","DOI":"10.1073\/pnas.0905184106","article-title":"Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process","volume":"106","author":"Okwor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parint.2014.10.003_bb0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14760584.7.8.1141","article-title":"Epaxal: a virosomal vaccine to prevent hepatitis A infection","volume":"7","author":"Bovier","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.parint.2014.10.003_bb0215","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.parint.2014.10.003_bb0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0225","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0169-4758(96)40010-2","article-title":"A simple method for quantifying Leishmania in tissues of infected animals","volume":"13","author":"Lima","year":"1997","journal-title":"Parasitol Today"},{"key":"10.1016\/j.parint.2014.10.003_bb0235","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1084\/jem.167.6.1927","article-title":"The dynamics of granuloma formation in experimental visceral leishmaniasis","volume":"167","author":"McElrath","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.parint.2014.10.003_bb0240","first-page":"37-4","article-title":"Enhancement of immune response and protection in BALB\/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition","volume":"74","author":"Badiee","year":"2009","journal-title":"Colloid Surf B Interface"},{"key":"10.1016\/j.parint.2014.10.003_bb0245","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.parint.2014.10.003_bb0250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1590\/S0074-02762010000600015","article-title":"Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB\/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production","volume":"105","author":"Grenfell","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.parint.2014.10.003_bb0255","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0264-410X(00)00401-1","article-title":"Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers","volume":"19","author":"Satti","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.parint.2014.10.003_bb0260","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1371\/journal.pntd.0001429","article-title":"Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy:high immunogenicity and protection","volume":"5","author":"Mazumder","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.parint.2014.10.003_bb0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"22","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0270","first-page":"3169","article-title":"Adjuvant effect of saponins isolated from the sepal of Physalis alkekengi L. var. francheti (Mast.) Makino fruit on the immune responses to ovalbumin in mice","volume":"5","author":"Liu","year":"2011","journal-title":"J Med Plants Res"},{"key":"10.1016\/j.parint.2014.10.003_bb0275","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.parint.2014.10.003_bb0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3347\/kjp.2006.44.1.43","article-title":"Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice","volume":"44","author":"Mohammadi","year":"2006","journal-title":"Korean J Parasitol"},{"key":"10.1016\/j.parint.2014.10.003_bb0285","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.vaccine.2005.07.087","article-title":"Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine","volume":"24","author":"Marshall","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0290","doi-asserted-by":"crossref","first-page":"1499-04","DOI":"10.1128\/CVI.00153-07","article-title":"Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome","volume":"14","author":"Morefield","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0295","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1128\/JVI.00928-10","article-title":"TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector","volume":"84","author":"Rhee","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.parint.2014.10.003_bb0300","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.1202801","article-title":"Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit longterm protective immunity in BALB\/c mice","volume":"190","author":"Dey","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0305","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI113969","article-title":"Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated","volume":"83","author":"Carvalho","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.parint.2014.10.003_bb0310","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","article-title":"Interleukin 10 production correlates with pathology in human Leishmania donovani infections","volume":"92","author":"Ghalib","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.parint.2014.10.003_bb0315","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T","article-title":"IL-10 mediates susceptibility to Leishmania donovani infection","volume":"31","author":"Murphy","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.parint.2014.10.003_bb0320","first-page":"107","article-title":"720 is more effective than BCG as an adjuvant for Leishmania killed vaccine in BALB\/c mice","volume":"7","author":"Mutiso","year":"2009","journal-title":"IJIB"},{"key":"10.1016\/j.parint.2014.10.003_bb0325","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1006\/cyto.2000.0694","article-title":"IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis","volume":"12","author":"Bacellar","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.parint.2014.10.003_bb0330","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0335","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00ae vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2014.10.003_bb0340","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(99)00064-2","article-title":"Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells","volume":"41","author":"Rao","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.parint.2014.10.003_bb0345","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1128\/IAI.01739-07","article-title":"Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection","volume":"77","author":"Bhowmick","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.parint.2014.10.003_bb0350","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Khan","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"10.1016\/j.parint.2014.10.003_bb0355","doi-asserted-by":"crossref","first-page":"e1000484","DOI":"10.1371\/journal.ppat.1000484","article-title":"Vector transmission of Leishmania abrogates vaccine-induced protective immunity","volume":"5","author":"Peters","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.parint.2014.10.003_bb0360","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/jid.2012.315","article-title":"Delayed-type hypersensitivity to sandfly saliva in humans from a leishmaniasis-endemic area of MaliisTh1-mediated and persists to midlife","volume":"133","author":"Oliveira","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576914001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576914001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T02:13:25Z","timestamp":1689560005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383576914001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1383576914001391"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2014.10.003","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2014.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}